Selpercatinib‐Induced Deep Skin Fissures Triggered by Mechanical Friction in a Patient With RET Fusion‐Positive Lung Adenocarcinoma [PDF]
Respirology Case ReportsWe report a case of selpercatinib‐induced deep skin fissures in a patient with RET fusion‐positive lung adenocarcinoma. Minor mechanical abrasions triggered severe fingertip fissures, which were likely exacerbated by selpercatinib‐related VEGF receptor ...
Tomoyuki Ikeuchi +4 more
doaj +3 more sources
Pharmaceuticals, 2021 Selpercatinib is a targeted, FDA-approved, oral, small-molecule inhibitor for the treatment of rearranged during transfection (RET) proto-oncogene mutation-positive cancer.
Rolf W Sparidans +2 more
exaly +3 more sources
JTO Clinical and Research Reports, 2023 Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced RET-rearranged NSCLC. We present a case of pralsetinib-related pneumonitis and leptomeningeal and brain metastases progression during treatment suspension for ...
Sanjay Popat
exaly +3 more sources
Mechanistic insights into voriconazole-exacerbated selpercatinib-induced thrombocytopenia: a pharmacokinetic interaction case report [PDF]
Frontiers in OncologyThis paper reports a case of Grade IV thrombocytopenia in a 65-year-old male patient with advanced lung cancer after 4 days of concurrent treatment with selpercatinib and voriconazole.
Haochun Tang +5 more
doaj +2 more sources
Selpercatinib mitigates microglia-mediated neuroinflammation by inhibiting RET signaling and NLRP3 inflammasome activation [PDF]
Frontiers in ImmunologyBackgroundSelpercatinib is a highly selective rearranged during transfection (RET) receptor tyrosine kinase inhibitor approved for RET fusion-positive cancers and known to penetrate the blood–brain barrier.
Jung Ki Min +12 more
doaj +2 more sources
Durable Response to Selpercatinib in Metastatic Colorectal Cancer Harboring a Novel TIMM23B::RET Fusion: A Case Report [PDF]
Current OncologyRET fusions are rare but actionable oncogenic drivers in metastatic colorectal cancer (mCRC), occurring in a small molecular subset with limited clinical evidence for selective RET inhibition.
Ziyan Tong +3 more
doaj +2 more sources
Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib [PDF]
Frontiers in OncologySelpercatinib is a highly selective RET inhibitor with potent activity in RET-driven malignancies. Zoledronic acid is a standard bone-modifying agent for bone metastases, but its potential to induce hyperprogressive disease (HPD) is unclear. We present a
Junqi Liu, FengJiao He
doaj +2 more sources
Real-world clinical responses to selpercatinib in RET M918T-mutant medullary thyroid carcinoma [PDF]
Discover OncologyBackground RET alterations, especially the M918T mutation, contribute to the development of aggressive medullary thyroid carcinoma (MTC). Selective RET inhibition has shown greater efficacy compared to VEGFR-targeting multikinase inhibitors (MKIs ...
Ilker Nihat Ökten, Tuba Baydaş
doaj +2 more sources
Frontiers in OncologyBackgroundRearranged during transfection (RET) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential.
Andrea Bianco, Fabio Perrotta
exaly +3 more sources
Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis
HeliyonBackground: Selpercatinib is effective in the treatment of RET-altered medullary thyroid carcinoma (MTC). This study aimed to evaluate the efficacy and safety of selpercatinib in the treatment of patients with RET-altered MTC.
Dongmei Huang +3 more
exaly +3 more sources